Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novan, Inc.
  6. Summary
    NOVN   US66988N2053

NOVAN, INC.

(NOVN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
5.08(c) 5.04(c) 4.78(c) 4.97(c) 4.64(c) Last
399 809 261 506 295 750 236 461 233 663 Volume
-1.17% -0.79% -5.16% +3.97% -6.64% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 3,06 M - -
Net income 2021 -29,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,66x
Yield 2021 -
Sales 2022 2,91 M - -
Net income 2022 -38,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,46x
Yield 2022 -
Capitalization 87,3 M 87,3 M -
Capi. / Sales 2021 28,6x
Capi. / Sales 2022 30,0x
Nbr of Employees 23
Free-Float 94,1%
More Financials
Company
Novan, Inc. is a late clinical-stage biotechnology company. The Company is focused on leveraging its nitric oxide (NO)-based technology platform, NITRICIL, to generate macromolecular new chemical entities (NCEs) to treat multiple indications in dermatology, men’s and women’s health, infectious diseases, and various other medical conditions. The Company has clinical-stage dermatology drug candidates with... 
Sector
Pharmaceuticals
Calendar
03/30Earnings Release
More about the company
Ratings of Novan, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about NOVAN, INC.
11/30NOVAN, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial O..
AQ
11/12Novan to Participate in the Virtual Investor Roundtable Event
GL
11/10NOVAN, INC. : Management's Discussion and Analysis of Financial Condition and Results of O..
AQ
11/10Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results - Form..
PU
11/10NOVAN, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
11/10Earnings Flash (NOVN) NOVAN Reports Q3 Revenue $737,000, vs. Street Est of $0.752M
MT
11/10NOVAN : Q3 Earnings Snapshot
AQ
11/10Novan, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Septem..
CI
11/09Novan Says Preclinical Data Back Plan to Advance COVID-19 Drug Candidate
MT
11/09Novan Plans to Advance SB019 for Treatment of Covid-19
DJ
11/09Novan Announces Favorable Preclinical Safety Data and Intent to Advance SB019 for Treat..
AQ
11/09Novan, Inc. Announces Favorable Preclinical Safety Data and Intent to Advance SB019 for..
CI
11/04Novan Announces Fireside Chat Hosted by Jonathan Aschoff, Ph.D. of ROTH Capital Partner..
AQ
11/03Novan to Report Third Quarter 2021 Financial Results on November 10, 2021
AQ
11/02Novan Receives Conditional FDA Acceptance for Antiviral Gel Brand Name
MT
More news
News in other languages on NOVAN, INC.
11/10Earnings Flash (NOVN) NOVAN annonce un revenu de 737 000 $ pour le troisième trimestre,..
11/09Novan affirme que les données précliniques appuient le plan d'avancement du candidat mé..
11/02Novan reçoit l'acceptation conditionnelle de la FDA pour le nom de marque du gel antivi..
10/26Hausse des actions, les résultats en soutien
09/23Le candidat au traitement des molluscums de Novan présente un profil de sécurité favora..
More news
Analyst Recommendations on NOVAN, INC.
More recommendations
Chart NOVAN, INC.
Duration : Period :
Novan, Inc. Technical Analysis Chart | NOVN | US66988N2053 | MarketScreener
Technical analysis trends NOVAN, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 4,64 $
Average target price 36,00 $
Spread / Average Target 676%
EPS Revisions
Managers and Directors
Paula Brown Stafford Chairman, President & Chief Executive Officer
John M. Gay Chief Financial Officer, Secretary & VP
Tomoko Maeda-Chubachi Chief Medical Officer
Carri Geer Chief Technology Officer & Senior Vice President
Robert Alexander Ingram Independent Director
Sector and Competitors